Clinical trials: Healthy Adult Immune Response
Malaria, Vivax
Study of Controlled Human Plasmodium Vivax Infection
This is a sporozoite-challenge clinical study with the primary aim of assessing the safety and feasibility of controlled human P. vivax malaria infection in two healthy volunteers.
- Trial name
- VAC068 (NCT03377296)
- Testing
- Plasmodium vivax infection, Collection of 250mL blood from each volunteer (N=2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
RATIONALE: The influenza vaccine may help prevent flu in patients who have undergone stem cell transplant. PURPOSE: This clinical trial is studying how well the influenza vaccine works in preventing flu in patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00952185
- Testing
- cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Epstein Barr Virus (EBV) Infection
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
To evaluate the safety, immune-response and efficacy of GSK Biologicals' EBV vaccine in a population at risk of developing infectious mononucleosis.
- Trial name
- NCT00430534
- Testing
- EBV vaccine (268664)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Henogen
Cytomegalovirus
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative.
- Trial name
- NCT01195571
- Testing
- cmv vaccine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CMV Research Foundation
Influenza
Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines
This project aims to test the hypothesis that oral consumption of a specific strain of the probiotic bacterium Lactobacillus fermentum (trademarked PCC®) is able to significantly enhance the immune response to a vaccine for…
- Trial name
- NCT00294788
- Testing
- Fluvax, PCC® (Lactobacillus fermentum VRI 003)
- Where
- Australia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Probiomics Ltd
Grippe, Influenza
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza.
- Conditions
- Grippe, Influenza, Vaccines
- Trial name
- NCT06179446
- Testing
- pdmFlu vaccine, Licensed influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with…
- Trial name
- NCT02207920
- Testing
- AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.
- Trial name
- RSV-OA=ADJ-020 (NCT05966090)
- Testing
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Where
- 31 sites in United States, Canada
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00270699
- Testing
- rDEN4delta30-200,201
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Adult Immune Response
Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults
Background: Human immunodeficiency virus (HIV) infection is a serious disease. There is no cure or vaccine to prevent infection. Using antibodies might be a good way to treat or prevent HIV.
- Trial name
- NCT03565315
- Testing
- VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.
- Trial name
- NCT01927835
- Testing
- DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Healthy Volunteers)
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza…
- Trial name
- NCT07305207
- Testing
- Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Healthy
3Sm Challenge Model Protocol
The 3Sm challenge study is a small clinical study in eight healthy volunteers who will be injected with a protein which includes a short portion ('3Sm peptide') which is derived from a part (the '3S region') of the coat protein…
- Trial name
- NCT04753892
- Testing
- 3SM2-G-CRM197 with squalene adjuvant
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Healthy Subject, Immunity
The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune)
This study will evaluate the capacity of botanical extracts to modulate immune mechanisms compared to a placebo group in healthy volunteers.
- Trial name
- B-4-Immune (NCT05117385)
- Testing
- Botanical extract
- Where
- France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
HIV Infections
Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda
Currently, no vaccine prevents HIV infection. This study will test the safety and immune responses of an HIV-1 DNA vaccine in HIV-uninfected adults in a Ugandan population.
- Trial name
- NCT01549470
- Testing
- VRC-HIVDNA009-00-VP
- Where
- Uganda
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to two HIV vaccine formulations, rMVA-HIV and rFPV-HIV, alone and in combination, in HIV uninfected adults.
- Trial name
- NCT00083603
- Testing
- rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV
- Where
- 6 sites in United States, Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00375726
- Testing
- rDEN3/4delta30(ME)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00618605
- Testing
- Ad26.ENVA.01 HIV-1 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)